PL372867A1 - Kompozycja farmaceutyczna zawierająca melatoninę - Google Patents

Kompozycja farmaceutyczna zawierająca melatoninę

Info

Publication number
PL372867A1
PL372867A1 PL03372867A PL37286703A PL372867A1 PL 372867 A1 PL372867 A1 PL 372867A1 PL 03372867 A PL03372867 A PL 03372867A PL 37286703 A PL37286703 A PL 37286703A PL 372867 A1 PL372867 A1 PL 372867A1
Authority
PL
Poland
Prior art keywords
melatonin
pharmaceutical formulation
barbiturate
effected
short
Prior art date
Application number
PL03372867A
Other languages
English (en)
Other versions
PL209922B1 (pl
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL372867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of PL372867A1 publication Critical patent/PL372867A1/pl
Publication of PL209922B1 publication Critical patent/PL209922B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
PL372867A 2002-04-28 2003-03-20 Kompozycja farmaceutyczna zawierająca melatoninę PL209922B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds

Publications (2)

Publication Number Publication Date
PL372867A1 true PL372867A1 (pl) 2005-08-08
PL209922B1 PL209922B1 (pl) 2011-11-30

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
PL372867A PL209922B1 (pl) 2002-04-28 2003-03-20 Kompozycja farmaceutyczna zawierająca melatoninę

Country Status (29)

Country Link
US (1) US20050175692A1 (pl)
EP (1) EP1494650B1 (pl)
JP (1) JP2005527583A (pl)
KR (1) KR101000624B1 (pl)
CN (1) CN100386070C (pl)
AR (1) AR039232A1 (pl)
AT (1) ATE507831T1 (pl)
AU (1) AU2003227304B2 (pl)
BR (1) BR0308762A (pl)
CA (1) CA2477516C (pl)
DE (1) DE60336999D1 (pl)
DK (1) DK1494650T3 (pl)
EA (1) EA007954B1 (pl)
ES (1) ES2366116T3 (pl)
GT (1) GT200300064A (pl)
HN (1) HN2003000115A (pl)
IL (1) IL149377A (pl)
IS (1) IS2858B (pl)
MX (1) MXPA04009893A (pl)
NO (1) NO332525B1 (pl)
NZ (1) NZ536298A (pl)
PE (1) PE20040161A1 (pl)
PL (1) PL209922B1 (pl)
PT (1) PT1494650E (pl)
TW (1) TW200305404A (pl)
UA (1) UA86924C2 (pl)
UY (1) UY27753A1 (pl)
WO (1) WO2003086352A1 (pl)
ZA (1) ZA200407563B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696959A2 (en) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技(北京)有限公司 一种美乐托宁缓释剂、其制备方法及其应用
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP2570126B1 (en) * 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
MX386987B (es) 2016-10-31 2025-03-19 Neurim Pharma 1991 Mini-tabletas de melatonina y métodos de fabricación de las mismas.
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物
BR112022012199A2 (pt) * 2020-01-17 2022-09-13 Nestle Sa Forma de dosagem com péletes de melatonina de liberação sustentada

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
WO1996023496A1 (en) * 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
CA2241666C (en) * 1996-03-08 2007-11-06 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
WO1997037670A1 (en) * 1996-04-10 1997-10-16 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
US6274604B1 (en) * 1996-07-17 2001-08-14 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
BR0009200A (pt) * 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
DE60336999D1 (de) 2011-06-16
GT200300064A (es) 2003-11-26
DK1494650T3 (da) 2011-08-08
UA86924C2 (ru) 2009-06-10
CA2477516C (en) 2012-12-11
CN1646098A (zh) 2005-07-27
AR039232A1 (es) 2005-02-09
TW200305404A (en) 2003-11-01
EP1494650A4 (en) 2006-07-12
KR20040101406A (ko) 2004-12-02
AU2003227304A2 (en) 2005-04-14
EA200401331A1 (ru) 2005-04-28
ES2366116T3 (es) 2011-10-17
US20050175692A1 (en) 2005-08-11
HK1075616A1 (zh) 2005-12-23
EP1494650A1 (en) 2005-01-12
ZA200407563B (en) 2005-11-30
PT1494650E (pt) 2011-08-18
NZ536298A (en) 2008-09-26
MXPA04009893A (es) 2005-06-17
PE20040161A1 (es) 2004-03-22
IS7492A (is) 2004-10-07
AU2003227304B2 (en) 2007-12-06
IL149377A (en) 2012-10-31
KR101000624B1 (ko) 2010-12-10
JP2005527583A (ja) 2005-09-15
WO2003086352A1 (en) 2003-10-23
CA2477516A1 (en) 2003-10-23
IS2858B (is) 2013-12-15
EP1494650B1 (en) 2011-05-04
ATE507831T1 (de) 2011-05-15
AU2003227304A1 (en) 2003-10-27
NO332525B1 (no) 2012-10-08
BR0308762A (pt) 2005-01-11
EA007954B1 (ru) 2007-02-27
UY27753A1 (es) 2003-05-30
CN100386070C (zh) 2008-05-07
IL149377A0 (en) 2009-02-11
HN2003000115A (es) 2004-04-20
NO20043576L (no) 2004-12-22
PL209922B1 (pl) 2011-11-30

Similar Documents

Publication Publication Date Title
PT1494650E (pt) FORMULAÇÃO FARMACjUTICA QUE INCLUI MELATONINA
SG145699A1 (en) Pyridazine derivatives and their use as therapeutic agents
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
SG145701A1 (en) Piperazine derivatives and their use as therapeutic agents
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
TW200505881A (en) Tri(cyclo) substituted amide compounds
NZ544472A (en) Compounds and therapeutical use thereof
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
MXPA05013147A (es) Preparacion solida.
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
SG146442A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
DE60112756D1 (de) Racecadotril enthaltende trockene pulverformulierung
HUP0401484A3 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine and pharmaceutical compositions containing the combination
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu
ITRM20030555A1 (it) Prodotto di igiene buccodentale per uso umano e veterinario a base di melatonina come principio attivo.
ITRM20020119A0 (it) Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
AU2003281257A1 (en) A novel use of rapamycin and structural analogues thereof
PL1663101T3 (pl) Postać stosowana do doustnego podawania substancji czynnych, witamin i/lub substancji odżywczych, zestaw i zastosowanie
ATE489073T1 (de) Melatonin-tagesdosierungseinheiten
AU2003240446A1 (en) Use of mob-5 in pain
IL164356A0 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy